JP2014506448A5 - - Google Patents

Download PDF

Info

Publication number
JP2014506448A5
JP2014506448A5 JP2013549784A JP2013549784A JP2014506448A5 JP 2014506448 A5 JP2014506448 A5 JP 2014506448A5 JP 2013549784 A JP2013549784 A JP 2013549784A JP 2013549784 A JP2013549784 A JP 2013549784A JP 2014506448 A5 JP2014506448 A5 JP 2014506448A5
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
binding fragment
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013549784A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506448A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/050595 external-priority patent/WO2012098089A1/en
Publication of JP2014506448A publication Critical patent/JP2014506448A/ja
Publication of JP2014506448A5 publication Critical patent/JP2014506448A5/ja
Pending legal-status Critical Current

Links

JP2013549784A 2011-01-19 2012-01-17 凝固因子の阻害剤に対する結合タンパク質 Pending JP2014506448A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11151410 2011-01-19
EP11151410.5 2011-01-19
PCT/EP2012/050595 WO2012098089A1 (en) 2011-01-19 2012-01-17 Binding proteins to inhibitors of coagulation factors

Publications (2)

Publication Number Publication Date
JP2014506448A JP2014506448A (ja) 2014-03-17
JP2014506448A5 true JP2014506448A5 (enExample) 2015-03-05

Family

ID=45491612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013549784A Pending JP2014506448A (ja) 2011-01-19 2012-01-17 凝固因子の阻害剤に対する結合タンパク質

Country Status (7)

Country Link
US (1) US20140050743A1 (enExample)
EP (1) EP2665751A1 (enExample)
JP (1) JP2014506448A (enExample)
CN (1) CN103619883A (enExample)
AR (1) AR084886A1 (enExample)
CA (1) CA2824885A1 (enExample)
WO (1) WO2012098089A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434690A4 (en) 2016-03-23 2020-04-01 Seoul National University R&DB Foundation ANTIBODY BINDING TO HULL GLYCOPROTEIN OF HEAVY-FEVER-WITH-THROMBOZYTOPENIA-SYNDROME-VIRUS AND THE USE THEREOF
GB201618432D0 (en) 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
KR20190112747A (ko) 2017-02-01 2019-10-07 노보 노르디스크 에이/에스 응고촉진 항체
NL2036011B1 (en) * 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
US6669937B2 (en) * 2000-04-20 2003-12-30 The Board Of Trustees Of The University Of Arkansas Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
RU2319699C2 (ru) 2001-06-20 2008-03-20 Дайити Санкио Компани, Лимитед Производные диаминов
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
EP1427415B1 (en) 2001-09-21 2009-08-12 Brystol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor xa inhibitors
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028320A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
EP2193196B1 (en) * 2007-09-28 2016-07-13 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
EP2364165B1 (en) * 2008-11-14 2018-01-03 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
TWI513466B (zh) * 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑

Similar Documents

Publication Publication Date Title
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
ES2641294T3 (es) Nuevo anticuerpo para el diagnóstico y/o el pronóstico del cáncer
RU2018132044A (ru) Антитела против тау
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
BR112013008765B8 (pt) Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa
EA201790757A1 (ru) Связывающие антиген cd27l белки
JP2014061000A5 (enExample)
WO2013051878A3 (en) Antibody specifically binding to epitope in sema domain of c-met
CY1118540T1 (el) Μονοκλωνικα αντισωματα
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
JP2012143232A5 (enExample)
RU2012142230A (ru) Антитела против csf-1r человека и их применение
TR201909531T4 (tr) Anti-il-17 anti̇korlari kullanilarak anki̇lozan spondi̇li̇t tedavi̇ etme yöntemleri̇
JP2020524510A5 (enExample)
MX2011008843A (es) Anticuerpos humanizados que se unen a cd19 y sus usos.
WO2012088247A3 (en) Anti-c5/c5a/c5adesr antibodies and fragments
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
JP2014534237A5 (enExample)
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
JP2020507578A5 (enExample)
RU2015121617A (ru) Способы лечения заболеваний, ассоциированных с s. aureus
EA201270701A1 (ru) Ингибирующие металлопротеины антитела
JP2017506505A5 (enExample)
RU2015154792A (ru) Выделенный антиген лейкоцидина Staphylococcus aureus, антитело, специфически связывающееся с субъединицей LukGH и способ определения связывания или токсичности двухкомпонентного цитолизина LukGH Staphylococcus aureus
CA2863661C (en) Diagnostic peptides for lyme disease